{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:52:41Z","timestamp":1788501161420,"version":"build-2803163510"},"reference-count":36,"publisher":"BMJ","issue":"1","funder":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Raras","award":["ER20P3AC7624"],"award-info":[{"award-number":["ER20P3AC7624"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CM19\/00042"],"award-info":[{"award-number":["CM19\/00042"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FIS19\/01407"],"award-info":[{"award-number":["FIS19\/01407"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["SLT006\/17\/00131"],"award-info":[{"award-number":["SLT006\/17\/00131"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To study baseline serum neurofilament light chain (sNfL) levels as a prognostic biomarker in Guillain-Barr\u00e9 syndrome (GBS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We measured NfL in serum (98 samples) and cerebrospinal fluid (CSF) (24 samples) of patients with GBS prospectively included in the International GBS Outcome Study (IGOS) in Spain using single-molecule array (SiMoA) and compared them with 53 healthy controls (HCs). We performed multivariable regression to analyse the association between sNfL levels and functional outcome at 1\u2009year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients with GBS had higher NfL levels than HC in serum (55.49\u2009pg\/mL vs 9.83\u2009pg\/mL, p&lt;0.0001) and CSF (1308.5\u2009pg\/mL vs 440.24\u2009pg\/mL, p=0.034). Patients with preceding diarrhoea had higher sNfL than patients with respiratory symptoms or no preceding infection (134.90\u2009pg\/mL vs 47.86\u2009pg\/mL vs 38.02\u2009pg\/mL, p=0.016). sNfL levels correlated with Guillain-Barr\u00e9 Syndrome Disability Score and Inflammatory Rasch-built Overall Disability Scale (I-RODS) at every timepoint. Patients with pure motor variant and Miller Fisher syndrome showed higher sNfL levels than patients with sensorimotor GBS (162.18\u2009pg\/mL vs 95.50\u2009pg\/mL vs 38.02\u2009pg\/mL, p=0.025). Patients with acute motor axonal neuropathy cute motor axonal neuropathy had higher sNfL levels than other variants (190.55\u2009pg\/mL vs 46.79\u2009pg\/mL, p=0.013). sNfL returned to normal levels at 1\u2009year. High baseline sNfL levels were associated with inability to run (OR=1.65, 95%\u2009CI 1.14 to 2.40, p=0.009) and lower I-RODS (\u03b2 \u22122.60, 95% CI \u22124.66 to \u22120.54, p=0.014) at 1\u2009year. Cut-off points predicting clinically relevant outcomes at 1\u2009year with high specificity were calculated: inability to walk independently (&gt;319\u2009pg\/mL), inability to run (&gt;248\u2009pg\/mL) and ability to run (&lt;34\u2009pg\/mL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Baseline sNfL levels are increased in patients with GBS, are associated with disease severity and axonal variants and have an independent prognostic value in patients with GBS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jnnp-2020-323899","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T17:26:10Z","timestamp":1604597170000},"page":"70-77","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":74,"title":["Serum neurofilament light chain predicts long-term prognosis in Guillain-Barr\u00e9 syndrome patients"],"prefix":"10.1136","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1553-2224","authenticated-orcid":false,"given":"Lorena","family":"Mart\u00edn-Aguilar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pol","family":"Camps-Renom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinta","family":"Lleix\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elba","family":"Pascual-Go\u00f1i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"D\u00edaz-Manera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Rojas-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"De Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Cort\u00e9s-Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3819-3245","authenticated-orcid":false,"given":"Daniel","family":"Alcolea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Lle\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Casasnovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Homedes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Guti\u00e9rrez-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Concepci\u00f3n","family":"Jimeno-Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Berciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Sedano-Tous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Garc\u00eda-Sobrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Pardo-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celedonio","family":"M\u00e1rquez-Infante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4142-4283","authenticated-orcid":false,"given":"I\u00f1igo","family":"Rojas-Marcos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivonne","family":"Jeric\u00f3-Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Mart\u00ednez-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germ\u00e1n","family":"Mor\u00eds de la Tassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5151-988X","authenticated-orcid":false,"given":"Cristina","family":"Dom\u00ednguez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Illa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-8264","authenticated-orcid":false,"given":"Luis","family":"Querol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,11,5]]},"reference":[{"key":"2021022403000732000_92.1.70.1","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/ana.410270707","article-title":"Assessment of current diagnostic criteria for Guillain-Barr\u00e9 syndrome","volume":"27 Suppl","author":"Asbury","year":"1990","journal-title":"Ann Neurol"},{"key":"2021022403000732000_92.1.70.2","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1474-4422(07)70130-8","article-title":"A clinical prognostic scoring system for Guillain-Barr\u00e9 syndrome","volume":"6","author":"van Koningsveld","year":"2007","journal-title":"Lancet Neurol"},{"key":"2021022403000732000_92.1.70.3","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1212\/WNL.0b013e3182104407","article-title":"Early recognition of poor prognosis in Guillain-Barre syndrome","volume":"76","author":"Walgaard","year":"2011","journal-title":"Neurology"},{"key":"2021022403000732000_92.1.70.4","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/ana.21976","article-title":"Prediction of respiratory insufficiency in Guillain-Barr\u00e9 syndrome","volume":"67","author":"Walgaard","year":"2010","journal-title":"Ann Neurol"},{"key":"2021022403000732000_92.1.70.5","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"2021022403000732000_92.1.70.6","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","article-title":"Neurofilament light chain as a biomarker in neurological disorders","volume":"90","author":"Gaetani","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021022403000732000_92.1.70.7","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","article-title":"Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa","volume":"54","author":"Kuhle","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"2021022403000732000_92.1.70.8","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann Neurol"},{"key":"2021022403000732000_92.1.70.9","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1212\/01.wnl.0000237334.69665.92","article-title":"CSF neurofilament levels: a potential prognostic marker in Guillain-Barr\u00e9 syndrome","volume":"67","author":"Petzold","year":"2006","journal-title":"Neurology"},{"key":"2021022403000732000_92.1.70.10","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/mus.21239","article-title":"CSF protein biomarkers for proximal axonal damage improve prognostic accuracy in the acute phase of Guillain-Barr\u00e9 syndrome","volume":"40","author":"Petzold","year":"2009","journal-title":"Muscle Nerve"},{"key":"2021022403000732000_92.1.70.11","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/ane.12927","article-title":"Neurofilament light protein levels in cerebrospinal fluid predict long-term disability of Guillain-Barr\u00e9 syndrome: a pilot study","volume":"138","author":"Axelsson","year":"2018","journal-title":"Acta Neurol Scand"},{"key":"2021022403000732000_92.1.70.12","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/jns.12279","article-title":"Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies","volume":"23","author":"Mariotto","year":"2018","journal-title":"J Peripher Nerv Syst"},{"key":"2021022403000732000_92.1.70.13","doi-asserted-by":"crossref","first-page":"e75091","DOI":"10.1371\/journal.pone.0075091","article-title":"Increased neurofilament light chain blood levels in neurodegenerative neurological diseases","volume":"8","author":"Gaiottino","year":"2013","journal-title":"PLoS One"},{"key":"2021022403000732000_92.1.70.14","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-020-01737-0","article-title":"Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barr\u00e9 syndrome","volume":"17","author":"Altmann","year":"2020","journal-title":"J Neuroinflammation"},{"key":"2021022403000732000_92.1.70.15","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/jns.12209","article-title":"International Guillain-Barr\u00e9 syndrome outcome study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barr\u00e9 syndrome","volume":"22","author":"Jacobs","year":"2017","journal-title":"J Peripher Nerv Syst"},{"key":"2021022403000732000_92.1.70.16","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","article-title":"Guillain-Barr\u00e9 syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"29","author":"Sejvar","year":"2011","journal-title":"Vaccine"},{"key":"2021022403000732000_92.1.70.17","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrneurol.2014.138","article-title":"Guillain-Barr\u00e9 and Miller Fisher syndromes--new diagnostic classification","volume":"10","author":"Wakerley","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"2021022403000732000_92.1.70.18","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0140-6736(78)92644-2","article-title":"Controlled trial prednisolone in acute polyneuropathy","volume":"2","author":"Hughes","year":"1978","journal-title":"Lancet"},{"key":"2021022403000732000_92.1.70.19","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1212\/WNL.0b013e318208824b","article-title":"Rasch-built overall disability scale (R-ODS) for immune-mediated peripheral neuropathies","volume":"76","author":"van Nes","year":"2011","journal-title":"Neurology"},{"key":"2021022403000732000_92.1.70.20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/brain\/awt285","article-title":"Diagnosis of Guillain-Barr\u00e9 syndrome and validation of Brighton criteria","volume":"137","author":"Fokke","year":"2014","journal-title":"Brain"},{"key":"2021022403000732000_92.1.70.21","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1212\/WNL.56.6.758","article-title":"Preceding infections, immune factors, and outcome in Guillain-Barr\u00e9 syndrome","volume":"56","author":"Hadden","year":"2001","journal-title":"Neurology"},{"key":"2021022403000732000_92.1.70.22","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(16)00339-1","article-title":"Guillain-Barr\u00e9 syndrome","volume":"388","author":"Willison","year":"2016","journal-title":"Lancet"},{"key":"2021022403000732000_92.1.70.23","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1136\/jnnp.2004.051136","article-title":"Recovery patterns and long term prognosis for axonal Guillain-Barr\u00e9 syndrome","volume":"76","author":"Hiraga","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021022403000732000_92.1.70.24","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1136\/jnnp.70.4.560","article-title":"Indicators of rapid clinical recovery in Guillain-Barr\u00e9 syndrome","volume":"70","author":"Kuwabara","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021022403000732000_92.1.70.25","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/brain\/awy232","article-title":"Regional variation of Guillain-Barr\u00e9 syndrome","volume":"141","author":"Doets","year":"2018","journal-title":"Brain"},{"key":"2021022403000732000_92.1.70.26","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/jns.12319","article-title":"Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy","volume":"24","author":"van Lieverloo","year":"2019","journal-title":"J Peripher Nerv Syst"},{"key":"2021022403000732000_92.1.70.27","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1212\/WNL.0000000000004932","article-title":"Plasma neurofilament light chain concentration in the inherited peripheral neuropathies","volume":"90","author":"Sandelius","year":"2018","journal-title":"Neurology"},{"key":"2021022403000732000_92.1.70.28","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/jns.12350","article-title":"Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis","volume":"24","author":"Kapoor","year":"2019","journal-title":"J Peripher Nerv Syst"},{"key":"2021022403000732000_92.1.70.29","first-page":"57","article-title":"The Miller Fisher syndrome. review of the literature","volume":"12","author":"Berlit","year":"1992","journal-title":"J Clin Neuroophthalmol"},{"key":"2021022403000732000_92.1.70.30","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/jnnp.2008.154765","article-title":"Cerebral glucose metabolism in Fisher syndrome","volume":"80","author":"Kim","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021022403000732000_92.1.70.31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40673-015-0021-3","article-title":"Miller-Fisher syndrome: is the ataxia central or peripheral?","volume":"2","author":"Sandler","year":"2015","journal-title":"Cerebellum Ataxias"},{"key":"2021022403000732000_92.1.70.32","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/jnnp-2018-319190","article-title":"Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studies","volume":"90","author":"Martin","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021022403000732000_92.1.70.33","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1212\/WNL.55.4.552","article-title":"Perineurium contributes to axonal damage in acute inflammatory demyelinating polyneuropathy","volume":"55","author":"Berciano","year":"2000","journal-title":"Neurology"},{"key":"2021022403000732000_92.1.70.34","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.clinph.2014.06.051","article-title":"Spinal nerve involvement in early Guillain-Barr\u00e9 syndrome: a clinico-electrophysiological, ultrasonographic and pathological study","volume":"126","author":"Gallardo","year":"2015","journal-title":"Clin Neurophysiol"},{"key":"2021022403000732000_92.1.70.35","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1474-4422(18)30114-5","article-title":"Safety and efficacy of eculizumab in Guillain-Barr\u00e9 syndrome: a multicentre, double-blind, randomised phase 2 trial","volume":"17","author":"Misawa","year":"2018","journal-title":"Lancet Neurol"},{"key":"2021022403000732000_92.1.70.36","doi-asserted-by":"crossref","first-page":"1081-1089","DOI":"10.1002\/acn3.795","article-title":"Blood neurofilament light as a potential endpoint in phase 2 studies in MS","volume":"6","author":"Sormani","year":"2019","journal-title":"Ann Clin Transl Neurol"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2020-323899","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T10:48:15Z","timestamp":1698317295000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2020-323899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,5]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12,15]]},"published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1136\/jnnp-2020-323899"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2020-323899","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.03.24.20042200","asserted-by":"object"}]},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,5]]}}}